A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy

Wenli Qiu; Huifeng Zhang; Xiao Chen; Lina Song; Wenjing Cui; Shuai Ren; Yajie Wang; Kai Guo; Donghui Li; Rong Chen; Zhongqiu Wang

doi:10.2217/nnm-2019-0063

A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy

Wenli Qiu, Huifeng Zhang, Xiao Chen, Lina Song, Wenjing Cui, Shuai Ren, Yajie Wang, Kai Guo, Donghui Li, Rong Chen, Zhongqiu Wang

GI Medical Oncology

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Aim: Biomarker-targeted nanocarrier holds promise for early diagnosis and effective therapy of cancer. Materials & methods: This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer in vitro and in vivo. Results: Blood biochemical and histological analyses show that the in vivo toxicity of GPC1-GEM-nanoparticles (NPs) was negligible. Both in vitro and in vivo studies demonstrate that GPC1-GEM-NPs can be used as NIRF/MR contrast agent for pancreatic cancer detection. Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls. Conclusion: This novel theranostic nanoplatform provides early diagnostic and effective therapeutic potential for pancreatic cancer.

Original language	English (US)
Pages (from-to)	2339-2353
Number of pages	15
Journal	Nanomedicine
Volume	14
Issue number	17
DOIs	https://doi.org/10.2217/nnm-2019-0063
State	Published - 2019

Keywords

GPC1
gemcitabine
multimodal imaging
targeted therapy
theranostic nanoplatform

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
General Materials Science

Access to Document

10.2217/nnm-2019-0063

Cite this

@article{6b41b6a729e647f6a0857c275d98770c,

title = "A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy",

abstract = "Aim: Biomarker-targeted nanocarrier holds promise for early diagnosis and effective therapy of cancer. Materials & methods: This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer in vitro and in vivo. Results: Blood biochemical and histological analyses show that the in vivo toxicity of GPC1-GEM-nanoparticles (NPs) was negligible. Both in vitro and in vivo studies demonstrate that GPC1-GEM-NPs can be used as NIRF/MR contrast agent for pancreatic cancer detection. Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls. Conclusion: This novel theranostic nanoplatform provides early diagnostic and effective therapeutic potential for pancreatic cancer.",

keywords = "GPC1, gemcitabine, multimodal imaging, targeted therapy, theranostic nanoplatform",

author = "Wenli Qiu and Huifeng Zhang and Xiao Chen and Lina Song and Wenjing Cui and Shuai Ren and Yajie Wang and Kai Guo and Donghui Li and Rong Chen and Zhongqiu Wang",

note = "Funding Information: This work is supported by the National Natural Science Foundation of China (grant no. 81771899) and Primary Research & Development Plan of Jiangsu Province (BE2017772). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2019 {\textcopyright} 2019 Future Medicine Ltd.",

year = "2019",

doi = "10.2217/nnm-2019-0063",

language = "English (US)",

volume = "14",

pages = "2339--2353",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "17",

}

TY - JOUR

T1 - A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy

AU - Qiu, Wenli

AU - Zhang, Huifeng

AU - Chen, Xiao

AU - Song, Lina

AU - Cui, Wenjing

AU - Ren, Shuai

AU - Wang, Yajie

AU - Guo, Kai

AU - Li, Donghui

AU - Chen, Rong

AU - Wang, Zhongqiu

N1 - Funding Information: This work is supported by the National Natural Science Foundation of China (grant no. 81771899) and Primary Research & Development Plan of Jiangsu Province (BE2017772). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2019 © 2019 Future Medicine Ltd.

PY - 2019

Y1 - 2019

N2 - Aim: Biomarker-targeted nanocarrier holds promise for early diagnosis and effective therapy of cancer. Materials & methods: This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer in vitro and in vivo. Results: Blood biochemical and histological analyses show that the in vivo toxicity of GPC1-GEM-nanoparticles (NPs) was negligible. Both in vitro and in vivo studies demonstrate that GPC1-GEM-NPs can be used as NIRF/MR contrast agent for pancreatic cancer detection. Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls. Conclusion: This novel theranostic nanoplatform provides early diagnostic and effective therapeutic potential for pancreatic cancer.

AB - Aim: Biomarker-targeted nanocarrier holds promise for early diagnosis and effective therapy of cancer. Materials & methods: This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer in vitro and in vivo. Results: Blood biochemical and histological analyses show that the in vivo toxicity of GPC1-GEM-nanoparticles (NPs) was negligible. Both in vitro and in vivo studies demonstrate that GPC1-GEM-NPs can be used as NIRF/MR contrast agent for pancreatic cancer detection. Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls. Conclusion: This novel theranostic nanoplatform provides early diagnostic and effective therapeutic potential for pancreatic cancer.

KW - GPC1

KW - gemcitabine

KW - multimodal imaging

KW - targeted therapy

KW - theranostic nanoplatform

UR - http://www.scopus.com/inward/record.url?scp=85072057006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072057006&partnerID=8YFLogxK

U2 - 10.2217/nnm-2019-0063

DO - 10.2217/nnm-2019-0063

M3 - Article

C2 - 31414945

AN - SCOPUS:85072057006

SN - 1743-5889

VL - 14

SP - 2339

EP - 2353

JO - Nanomedicine

JF - Nanomedicine

IS - 17

ER -

A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this